Amid re­peat­ed stum­bles, Pfiz­er and Eli Lil­ly tout their an­ti-NGF pain drug tanezum­ab — but ques­tions linger

Pfiz­er and Eli Lil­ly have start­ed to make their late-stage case for tanezum­ab, out­lin­ing some pos­i­tive re­sults on pain but rais­ing some se­ri­ous is­sues about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER